Rizatriptan (Maxalt) vs Sumatriptan (Tosymra)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Migraine

Shared mechanism: 5-HT1B/1D receptor · full Migraine pipeline

Rizatriptan (Maxalt)

Marketed by Organon

Approved in Migrainesmall molecule
Partial signal

NCT00897949 · Phase 3 · completed

This was a large randomized, double-blind, placebo-controlled trial, and both rizatriptan doses significantly increased pain relief at 2 hours compared with placebo. The sources available for this trial do not report a sample-size calculation or a planned enrolment, so it cannot be confirmed that the trial was adequately powered.

Reported efficacy

Pain Relief at 2 Hours After the Initial Dose of Test Drug (2 hours after initial dose of test drug): Pain relief at 2 hours after the first dose: rizatriptan 5 mg 62% (285/457) and 10 mg 71% (322/455) vs placebo 35% (106/302), significantly higher for both doses (Teall et al., Headache 1998; CT.gov posted counts). (met)

Result source: NCT00897949

Sumatriptan (Tosymra)

Marketed by Tonix Pharmaceuticals and partners

Approved in Migrainesmall molecule
Weak signal

NCT02279082 · Phase 3 · completed

This was a single-arm, open-label study of 167 participants with no randomization, blinding, or comparator arm. Its primary endpoint was the number of participants with treatment-emergent adverse events, reported in 120 participants over six months, so the study provides descriptive safety information but cannot establish comparative safety or treatment efficacy.

Reported efficacy

Number of Participants With Treatment Emergent Adverse Events (6 months): Number of Participants With Treatment Emergent Adverse Events (6 months): DFN-02 120 Participants (not_applicable)

Result source: NCT02279082

Results for Migraine

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Rizatriptan (Maxalt): registry results are on file for Migraine, but their comparison mappings are not yet available.

Sumatriptan (Tosymra): registry results are on file for Migraine, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Rizatriptan (Maxalt)'s landscape · Sumatriptan (Tosymra)'s landscape